Prognostic factors affecting survival in early-stage HER2-positive breast cancer treated with adjuvant therapy

Öz

Abstract Purpose: This study aimed to identify the prognostic and predictive factors affecting survival in patients with early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer who received adjuvant treatment. Materials and methods: A retrospective analysis was conducted on 124 female patients diagnosed with early-stage HER2-positive breast cancer at Pamukkale University Faculty of Medicine between January 2014 and December 2019. Clinicopathological characteristics, treatment regimens, and laboratory findings were analyzed. Survival analyses were performed using the Kaplan-Meier method, and factors influencing survival were evaluated using Cox regression analysis. Results: The mean follow-up duration were 63.9 months. The mean overall survival and progression-free survival were 65.1 and 58.8 months, respectively. Lymph node involvement greater than three, elevated Cancer Antigen 15-3 (CA15-3) (>25 U/mL), and high lactate dehydrogenase (LDH) levels (>214 U/L) were significantly associated with shorter progression-free survival (p<0.05). High CA15-3 levels were also correlated with decreased overall survival (p<0.05). Other parameters, including age, tumour size, Ki67 index, histologic and nuclear grade, lymphovascular invasion, chemotherapy regimen, and neutrophil-to-lymphocyte ratio (NLR), were not significantly related to survival outcomes. Conclusion: CA15-3 and LDH levels, along with the number of involved lymph nodes, were identified as potential prognostic indicators of early-stage HER2-positive breast cancer. These biomarkers may help guide clinical decision-making and patient follow-up. Further large-scale studies are required to validate these findings

Anahtar Kelimeler

• HER2-positive breast cancer
• early stage
• lymph node
• CA15-3
• LDH

Destekleyen Kurum

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors declare that they received no financial support for the research, authorship, and/or publication of this article.

Etik Beyan

Ethical approval for this study was obtained from the Pamukkale University Faculty of Medicine Non-Interventional Clinical Research Ethics Committee (approval date: January 7, 2020; approval number: 01). The study was conducted in accordance with the principles of the Declaration of Helsinki. All data were evaluated retrospectively, and patient confidentiality was maintained.

Adjuvan tedavi verilen erken evre HER2 pozitif meme kanserli hastalarda sağkalıma etki eden faktörler

Öz

Öz Amaç: Bu çalışmanın amacı, adjuvan tedavi alan erken evre insan epidermal büyüme faktörü reseptörü 2 (HER2) pozitif meme kanserli hastalarda sağkalımı etkileyen prognostik ve prediktif faktörleri belirlemektir. Gereç ve yöntem: Pamukkale Üniversitesi Tıp Fakültesi’nde Ocak 2014–Aralık 2019 tarihleri arasında erken evre HER2 pozitif meme kanseri tanısı alan 124 kadın hastanın verileri retrospektif olarak incelendi. Klinikopatolojik özellikler, tedavi rejimleri ve laboratuvar bulguları analiz edildi. Sağkalım analizleri Kaplan-Meier yöntemiyle, sağkalımı etkileyen faktörler ise Cox regresyon analizi ile değerlendirildi. Bulgular: Ortalama takip süresi 63,9 ay idi. Ortalama genel sağkalım 65,1 ay, progresyonsuz sağkalım 58,8 ay olarak bulundu. Üçten fazla lenf nodu tutulumu, yüksek kanser antijen 15-3 (CA15-3) (>25 U/mL) ve yüksek laktat dehidrogenaz (LDH) düzeyi (>214 U/L) progresyonsuz sağkalımı anlamlı olarak kısaltmaktaydı (p<0,05). Ayrıca yüksek CA15-3 düzeyi, genel sağkalımın da azalmasıyla ilişkili bulundu (p<0,05). Yaş, tümör boyutu, Ki67, histolojik ve nükleer grade, lenfovasküler invazyon, kemoterapi rejimi ve nötrofil/lenfosit oranı (NLR) ile sağkalım arasında anlamlı ilişki saptanmadı. Sonuç: CA15-3 ve LDH düzeyleri ile lenf nodu sayısı, erken evre HER2 pozitif meme kanserli hastalarda potansiyel prognostik göstergeler olarak belirlenmiştir. Bu biyobelirteçler, tedavi planlaması ve hasta takibinde klinisyenlere yol gösterici olabilir. Bulguların doğrulanması için daha geniş kapsamlı çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

• HER2 pozitif meme kanseri
• erken evre
• lenf nodu
• LDH
• CA15-3

Destekleyen Kurum

Bu çalışma, herhangi bir kurum, kuruluş veya fon tarafından maddi olarak desteklenmemiştir. Yazarlar, araştırma, yazarlık ve/veya makalenin yayımlanması sürecinde hiçbir finansal destek almadıklarını beyan ederler.

Etik Beyan

Bu çalışma için Pamukkale Üniversitesi Tıp Fakültesi Girişimsel Olmayan Klinik Araştırmalar Etik Kurulu’ndan 07.01.2020 tarihli ve 01 sayılı onay alınmıştır. Çalışma, Helsinki Bildirgesi ilkelerine uygun olarak gerçekleştirilmiştir. Tüm veriler retrospektif olarak değerlendirilmiş olup, hasta gizliliği korunmuştur.

Kaynakça

1. Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer, 144(8), 1941–1953. https://doi.org/10.1002/ijc.31937
2. Bernstein L. (2002). Epidemiology of endocrine-related risk factors for breast cancer. Journal of mammary gland biology and neoplasia, 7(1), 3–15. https://doi.org/10.1023/a:1015714305420
3. Vidal, M., Paré, L., & Prat, A. (2016). Molecular Classification of Breast Cancer. In: Jatoi, I., Rody, A. (eds) Management of Breast Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-46356-8_12
4. Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lønning, P. E., Børresen-Dale, A. L., Brown, P. O., & Botstein, D. (2000). Molecular portraits of human breast tumours. Nature, 406(6797), 747–752. https://doi.org/10.1038/35021093
5. Ahn, S., Woo, J. W., Lee, K., & Park, S. Y. (2020). HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. Journal of pathology and translational medicine, 54(1), 34–44. https://doi.org/10.4132/jptm.2019.11.03
6. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, N.Y.), 235(4785), 177–182. https://doi.org/10.1126/science.3798106
7. Güllüoğlu, B. M. (2008). Approach to common breast diseases: risk evaluation and screening strategies for breast cancer. Turkish Journal of Family Practice, 12(1), 9–17. https://doi.org/10.2399/tahd.08.009
8. Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: a cancer journal for clinicians, 70(1), 7–30. https://doi.org/10.3322/caac.21590

9. Ozmen, V. (2008). Breast cancer in the World and Turkey. Journal of Breast Health, 4(2), 2–5.
10. Gui, Y., Liu, X., Chen, X., Yang, X., Li, S., Pan, Q., Luo, X., & Chen, L. (2019). A Network Meta-Analysis of Surgical Treatment in Patients With Early Breast Cancer. Journal of the National Cancer Institute, 111(9), 903–915. https://doi.org/10.1093/jnci/djz105
11. Carter, C. L., Allen, C., & Henson, D. E. (1989). Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 63(1), 181–187. https://doi.org/10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h
12. Si, C., Jin, Y., Wang, H., & Zou, Q. (2014). Association between molecular subtypes and lymph node status in invasive breast cancer. International journal of clinical and experimental pathology, 7(10), 6800–6806.
13. Rakha, E. A., Reis-Filho, J. S., Baehner, F., Dabbs D. J., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., Palacios, J., Richardson, A. L., Schnitt, S. J., Schmitt, F. C., Tan, P. H., Tse, G. M., Badve, S., & Ellis, I. O. (2010). Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast cancer research : BCR, 12(4), 207. https://doi.org/10.1186/bcr2607
14. Elston, C. W., & Ellis, I. O. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19(5), 403–410. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
15. Oshiro, C., Yamasaki, M., Noda, Y., Nishimae, A., Takahashi, H., & Inaji, H. (2020). Comparative evaluation of nuclear and histological grades as prognostic factors for invasive breast cancer. Breast cancer (Tokyo, Japan), 27(5), 947–953. https://doi.org/10.1007/s12282-020-01093-0
16. Le Doussal, V., Tubiana-Hulin, M., Friedman, S., Hacene, K., Spyratos, F., & Brunet, M. (1989). Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer, 64(9), 1914–1921. https://doi.org/10.1002/1097-0142(19891101)64:9<1914::aid-cncr2820640926>3.0.co;2-g
17. Tsuda, H., Akiyama, F., Kurosumi, M., Sakamoto, G., & Watanabe, T. (1998). Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Japanese journal of clinical oncology, 28(8), 486–491. https://doi.org/10.1093/jjco/28.8.486
18. Denduluri, N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S. L., Hassett, M. J., Holloway, J. N., Hurria, A., King, T. A., Lyman, G. H., Partridge, A. H., Somerfield, M. R., Trudeau, M. E., Wolff, A. C., & Giordano, S. H. (2018). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36(23), 2433–2443. https://doi.org/10.1200/JCO.2018.78.8604
19. van Dongen, J. A., Voogd, A. C., Fentiman, I. S., Legrand, C., Sylvester, R. J., Tong, D., van der Schueren, E., Helle, P. A., van Zijl, K., & Bartelink, H. (2000). Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. Journal of the National Cancer Institute, 92(14), 1143–1150. https://doi.org/10.1093/jnci/92.14.1143
20. Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J. H., & Wolmark, N. (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. The New England journal of medicine, 347(16), 1233–1241. https://doi.org/10.1056/NEJMoa022152
21. Ethier, J. L., Desautels, D., Templeton, A., Shah, P. S., & Amir, E. (2017). Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast cancer research : BCR, 19(1), 2. https://doi.org/10.1186/s13058-016-0794-1
22. Li, Y., Shao, Y., Bai, L., & Zhou, X. (2018). Increased derived neutrophil-to-lymphocyte ratio and Breast Imaging-Reporting and Data System classification predict poor survival in patients with non-distant metastatic HER2+ breast cancer treated with neoadjuvant chemotherapy. Cancer management and research, 10, 3841–3847. https://doi.org/10.2147/CMAR.S174537
23. Araki, K., Ito, Y., Fukada, I., Kobayashi, K., Miyagawa, Y., Imamura, M., Kira, A., Takatsuka, Y., Egawa, C., Suwa, H., Ohno, S., & Miyoshi, Y. (2018). Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC cancer, 18(1), 982. https://doi.org/10.1186/s12885-018-4888-2
24. Ulas, A., Avci, N., Kos, T., Cubukcu, E., Olmez, O. F., Bulut, N., & Degirmenci, M. (2015). Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab? Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 20(3), 714–722.
25. Ding, N., Huang, J., Li, N., Yuan, J., Wang, S., & Xiao, Z. (2020). Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy. BMC cancer, 20(1), 235. https://doi.org/10.1186/s12885-020-06750-3
26. Ali, H. Q., Mahdi, N. K., & Al-Jowher, M. H. (2013). The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer. JPMA. The Journal of the Pakistan Medical Association, 63(9), 1138–1141.
27. Hashim Z. M. (2014). The significance of CA15-3 in breast cancer patients and its relationship to HER-2 receptor status. International journal of immunopathology and pharmacology, 27(1), 45–51. https://doi.org/10.1177/039463201402700107